Company: SNWV
Filing Date: 2025-10-01
Form Type: 8-K
Source: 0001628280-25-043491
Chunk: 0

Company: SANUWAVE Health, Inc.
Filing Date: 2025-10-01
Form: 8-K
Item: Item 5.02
Chunk 0
---
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 25, 2025, Daniel Coyle was appointed the Chief Operating Officer of Sanuwave Health, Inc. (the “ Company”). Mr. Coyle, age 35, was the Company’s Vice President of Engineering and Operations from October 2024 through September 2025, and a Program Director at Nextern, a medical device manufacturer, from September 2019 through September 2024.

Mr. Coyle has no family relationships with any executive officer or director of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Further, there are no arrangements or understandings between Mr. Coyle and any other person pursuant to which he was selected to become the Chief Operating Officer of the Company.

Effective upon his appointment, Mr. Coyle’s annualized base salary was increased to $225,000, and his annual cash bonus award opportunity for the remainder of 2025 was increased to 40% of his annual base salary. The Compensation Committee of the Company’s Board of Directors (the “ Board”) also approved an award of stock options (the “ Options”) to purchase 60,000 shares of the Company’s common stock, which Options shall be granted to Mr. Coyle on October 9, 2025 and shall vest and become exercisable in 12 equal installments on each quarterly anniversary of the grant date.

Immediately prior to Mr. Coyle’s appointment, Peter Stegagno, the Company’s former Chief Operating Officer, was removed from such position and appointed the Company’s Chief Regulatory Officer. In connection with this transition, the Board completed a detailed review of Mr. Stegagno’s new functions and responsibilities, and based upon such review, determined that he no longer satisfies the definition of “officer” set forth in Rule 16a-1(f) promulgated under the Securities Exchange Act of 1934 (the “ Exchange Act”) or the definition of “executive officer” set forth in Rule 3b-7 under the Exchange Act.

On September 25, 2025, Andrew Walko, the Company’s President, also was terminated without cause, effective as of October 24, 2025. The Company and Mr. Walko are negotiating the terms of a separation agreement, which